Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial.

ABSTRACT:

Aims/introduction

This trial assessed the efficacy and safety of the possibility of varying the daily injection time of once-daily, long-acting basal insulin degludec (IDeg) in Japanese patients with type 2 diabetes inadequately controlled with insulin glargine.

Materials and methods

This was a 26-week, multicenter, open-label, randomized, treat-to-target trial, with a 2 × 2 factorial design comparing IDeg flexible (allowing dosing ±8 h from an agreed dosing time) with IDeg fixed dosing (at the same time each day). It was carried out in 458 adult patients who were inadequately controlled on insulin glargine with or without oral antidiabetic drugs.

Results

The majority of doses were taken within 2 h of the agreed dosing time, showing a high level of adherence among Jap

SUBMITTER: Kadowaki T 

PROVIDER: S-EPMC5009133 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature